Povinnosti Zkoušejícího Investigator is responsible for the conduct of the Study at Institution. In particular, but without limitation, it is the Investigator’s duty to review and understand the information in the Investigator’s Brochure to ensure that all informed consent requirements are followed. IQVIA or Sponsor will ensure that all required reviews and approvals by applicable regulatory authorities and ECs are obtained. Zkoušející je odpovědný za provedení Studie ve Zdravotnickém zařízení. Konkrétně pak jde zejména, ale nejen o povinnost Zkoušejícího zkontrolovat a porozumět informacím obsaženým v Souboru informací pro zkoušejícího a zajistit dodržování všech požadavků týkajících se informovaného souhlasu. IQVIA nebo Zadavatel zajistí, že budou opatřena veškerá požadovaná kontrolní schválení od příslušných regulatorních úřadů a EK. Investigator agrees to provide a written declaration revealing Investigator’s possible economic or other interests, if any, in connection with the conduct of the Study or the Investigational Product, or the Sponsor. Zkoušející souhlasí, že poskytne písemné prohlášení vztahující se k potenciálním zájmům Zkoušejícího ekonomické či jiné povahy, či odhalí jiné zájmy, je-li jich, a to v souvislosti s prováděním této Studie či ve vztahu k Hodnocenému léčivu i ve vztahu k Zadavateli. Investigator agrees to provide a written declaration revealing Investigator’s disclosure obligations, if any, with the Institution in connection with the conduct of the Study and the Investigational Product. Zkoušející souhlasí, že poskytne písemné prohlášení, jež bude odhalovat závazky Zkoušejícího, jsou-li nějaké, a to vůči Zdravotnickému zařízení ve vztahu a v souvislosti s prováděním Studie a Hodnoceným léčivem. Investigator is duly licensed to conduct the Study and in good standing. Zkoušející má řádné a platné příslušné oprávnění k provádění Studie. Site agrees to provide prompt advance notice to Sponsor and IQVIA if Investigator will be terminating its employment relationship in the Institution or is otherwise no longer able to perform the Study. The appointment of a new Investigator must have the prior approval of Sponsor and IQVIA. Místo provádění klinického hodnocení souhlasí, že zašle předem promptní oznámení Zadavateli a IQVIA v případě, že Zkoušející ukončí pracovní poměr ve Zdravotnickém zařízení či nebude-li Zkoušející z jakéhokoli jiného důvodu schopen provádět Studii. Ustanovení nového Zkoušejícího bude podléhat předchozímu schválení Zadavatele a IQVIA.
India As used herein, “
Povinnosti Site and Institution’s personnel, including Study Staff shall not Místo provádění klinického hodnocení a zaměstnanci Zdravotnického zařízení, a to včetně Studijního personálu, nebudou
US Federal Government Use If software is licensed to Customer for use in the performance of a US Government prime contract or subcontract, Customer agrees that consistent with FAR 12.211 and 12.212, commercial computer software, documentation and technical data for commercial items are licensed under HP’s standard commercial license.
Europe Europe refers to the following countries: Germany, Andorra, Austria, Belgium, Bulgaria, Cyprus, Croatia, Denmark, Spain, Estonia, Finland, Metropolitan France, Gibraltar, Hungary, Greece, Ireland, Italy and Islands, Liechtenstein, Latvia, Lithuania, Luxembourg, Malta, Principality of Monaco, Norway, Netherlands, Poland, Portugal, Romania, United Kingdom, Slovakia, Slovenia, Czech Republic, San Marino, Sweden and Switzerland. Events covered for assistance Illness, injury or death during covered travel. Events covered for insurance ✓ Cancellation ✓ Late arrival ✓ Interruption of stay ✓ Forgotten item ✓ Replacement vehicle Execution of services The assistance services covered by this agreement can only be triggered with prior approval from MUTUAIDE ASSISTANCE. As a result, no expenditure made under the authority of the Beneficiaries may be reimbursed by MUTUAIDE ASSISTANCE. Excess Portion of the loss left to be paid by the Insured provided for in the policy in the event of indemnity following a loss. The excess can be expressed as an amount, percentage, in days, hours, or kilometres. Long-haul: “Long-haul” refers to travel to countries not listed in the “Medium-haul” definition.
Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.
MINISTRY/SCHOOL BOARD INITIATIVES ETFO will be an active participant in the consultation process to develop a Ministry of Education PPM regarding Ministry/School Board Initiatives.
Research, Science and Technology Cooperation 1. The aims of cooperation in research, science and technology, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to build on existing agreements already in place for cooperation on research, science and technology; (b) to encourage, where appropriate, government agencies, research institutions, universities, private companies and other research organizations in the Parties to conclude direct arrangements in support of cooperative activities, programs or projects within the framework of this Agreement, specially related to trade and commerce; and (c) to focus cooperative activities towards sectors where mutual and complementary interests exist, with special emphasis on information and communication technologies and software development to facilitate trade between the Parties. 2. The Parties will encourage and facilitate, as appropriate, the following activities including, but not limited to:
Information Technologies Cooperation 1. The aims of cooperation in Information Technologies sectors, carried out in the mutual interest of the Parties and in compliance with their policies, will be: (a) to focus on cooperative activities towards information technology areas where mutual and complementary interests exists; and (b) to build on existing agreements and arrangements already in place between the Parties. 2. Information Technologies cooperation may include, but not be limited to: (a) scientific and technical cooperation for the Software Industry of the Parties and encouraging cooperation in software development for populations with specific needs; (b) facilitate the cooperation on academic, industrial and entrepreneurial networks in the area of Information Technology; (c) encouraging exchange of experience on management and research and development for Information Technology Parks; (d) research and development on Information Technology products and services, integrating television, multimedia, and cellular telephones; and (e) encouraging exchange of experience for research and development in networks and telecommunications.
Pharmacy Benefits - Prescription Drugs and Diabetic Equipment or Supplies from a Pharmacy This plan covers prescription drugs listed on our formulary and diabetic equipment or supplies bought from a pharmacy as a pharmacy benefit. These benefits are administered by our Pharmacy Benefit Manager (PBM). Our formulary includes a tiered copayment structure and indicates that certain prescription drugs require preauthorization. If a prescription drug is not on our formulary, it is not covered. For specific coverage information or a copy of the most current formulary, please visit our website or call our Customer Service Department. Prescription drugs and diabetic equipment or supplies are covered when dispensed using the following guidelines: • the prescription must be medically necessary, consistent with the physician’s diagnosis, ordered by a physician whose license allows him or her to order it, filled at a pharmacy whose license allows such a prescription to be filled, and filled according to state and federal laws; • the prescription must consist of legend drugs that require a physician’s prescription under law, or compound medications made up of at least one legend drug requiring a physician’s prescription under law; • the prescription must be dispensed at the proper place of service as determined by our Pharmacy and Therapeutics Committee. For example, certain prescription drugs may only be covered when obtained from a specialty pharmacy; and • the prescription is limited to the quantities authorized by your physician not to exceed the quantity listed in the Summary of Pharmacy Benefits. Prescription drugs are subject to the benefit limits and the amount you pay shown in the Summary of Pharmacy Benefits.
